Suppr超能文献

相似文献

1
Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment.
Gastroenterology. 2022 Aug;163(2):386-402.e1. doi: 10.1053/j.gastro.2022.03.056. Epub 2022 Apr 7.
2
Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Expert Opin Investig Drugs. 2019 Feb;28(2):161-177. doi: 10.1080/13543784.2019.1557145. Epub 2018 Dec 16.
3
Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance.
Annu Rev Pathol. 2023 Jan 24;18:123-148. doi: 10.1146/annurev-pathmechdis-031621-024600. Epub 2022 Sep 21.
4
Perspectives in the treatment of pancreatic adenocarcinoma.
World J Gastroenterol. 2015 Aug 21;21(31):9297-316. doi: 10.3748/wjg.v21.i31.9297.
5
Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma.
Hepatobiliary Pancreat Dis Int. 2022 Feb;21(1):10-24. doi: 10.1016/j.hbpd.2021.08.012. Epub 2021 Sep 8.
6
The biological underpinnings of therapeutic resistance in pancreatic cancer.
Genes Dev. 2021 Jul 1;35(13-14):940-962. doi: 10.1101/gad.348523.121. Epub 2021 Jun 11.
7
Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy.
J Immunol. 2023 Apr 1;210(7):859-868. doi: 10.4049/jimmunol.2200660.
8
Update on the management of pancreatic cancer: surgery is not enough.
World J Gastroenterol. 2015 Mar 21;21(11):3157-65. doi: 10.3748/wjg.v21.i11.3157.
9
Pancreatic cancer: Advances and challenges.
Cell. 2023 Apr 13;186(8):1729-1754. doi: 10.1016/j.cell.2023.02.014.
10
Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies.
Surg Oncol. 2022 Aug;43:101803. doi: 10.1016/j.suronc.2022.101803. Epub 2022 Jul 7.

引用本文的文献

1
Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids.
Cancer Cell Int. 2025 Sep 13;25(1):321. doi: 10.1186/s12935-025-03969-7.
3
Polyphenols in Pancreatic Cancer Management: Exploring the Roles and Mechanisms of Resveratrol and Epigallocatechin.
Oncol Res. 2025 Aug 28;33(9):2243-2262. doi: 10.32604/or.2025.065222. eCollection 2025.
5
Prognostic value of nutritional risk assessment indices in patients with digestive system tumors.
BMC Cancer. 2025 Aug 27;25(1):1385. doi: 10.1186/s12885-025-14823-4.
8
Muscle strength and mass as predictors of pancreatic cancer: insights from the UK biobank.
BMC Cancer. 2025 Aug 20;25(1):1346. doi: 10.1186/s12885-025-14766-w.
9
A review of C/EBP α: a potential novel target for solid tumor intervention.
J Transl Med. 2025 Aug 11;23(1):894. doi: 10.1186/s12967-025-06884-7.
10
Proteomic insights into early pancreatic ductal adenocarcinoma biology and screening.
Discov Oncol. 2025 Aug 11;16(1):1531. doi: 10.1007/s12672-025-03317-1.

本文引用的文献

1
A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma.
Nat Cancer. 2020 Jan;1(1):59-74. doi: 10.1038/s43018-019-0010-1. Epub 2020 Jan 13.
2
The path to the clinic: a comprehensive review on direct KRAS inhibitors.
J Exp Clin Cancer Res. 2022 Jan 19;41(1):27. doi: 10.1186/s13046-021-02225-w.
3
Targeting Mutated KRAS Genes to Treat Solid Tumours.
Mol Diagn Ther. 2022 Jan;26(1):39-49. doi: 10.1007/s40291-021-00564-0. Epub 2021 Dec 16.
4
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer.
Cell. 2021 Dec 9;184(25):6119-6137.e26. doi: 10.1016/j.cell.2021.11.017.
5
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS Inhibitor.
J Med Chem. 2022 Feb 24;65(4):3123-3133. doi: 10.1021/acs.jmedchem.1c01688. Epub 2021 Dec 10.
6
Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals.
Gastroenterology. 2022 Mar;162(3):772-785.e4. doi: 10.1053/j.gastro.2021.10.014. Epub 2021 Oct 19.
7
Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance.
Cancer Metastasis Rev. 2021 Sep;40(3):837-862. doi: 10.1007/s10555-021-09981-3. Epub 2021 Sep 30.
8
The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions.
Cancer Metastasis Rev. 2021 Sep;40(3):675-689. doi: 10.1007/s10555-021-09988-w.
9
Uncertain Beginnings: Acinar and Ductal Cell Plasticity in the Development of Pancreatic Cancer.
Cell Mol Gastroenterol Hepatol. 2022;13(2):369-382. doi: 10.1016/j.jcmgh.2021.07.014. Epub 2021 Aug 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验